Impact of DHA intake in a mouse model of synucleinopathy
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Polyunsaturated fatty acids omega‐3 (n‐3 PUFA), such as docosahexaenoic acid (DHA), have been shown to prevent, and partially reverse, neurotoxin‐induced nigrostriatal denervation in animal models of Parkinson's disease (PD). However, the accumulation of &agr;‐synuclein (&agr;Syn) in cerebral tissues is equally important to the pathophysiology. To determine whether DHA intake improves various aspects related to synucleinopathy, ninety male mice overexpressing human &agr;Syn under the Thy‐1 promoter (Thy1‐&agr;Syn) were fed one of three diets (specially formulated control, low n‐3 PUFA or high DHA) and compared to non‐transgenic C57/BL6 littermate mice exposed to a control diet. Thy1‐&agr;Syn mice displayed impaired motor skills, lower dopaminergic neuronal counts within the substantia nigra (−13%) in parallel to decreased levels of the striatal dopamine transporter (DAT) (−24%), as well as reduced NeuN (−41%) and synaptic proteins PSD‐95 (−51%), synaptophysin (−80%) and vesicular acetylcholine transporter (VChAT) (−40%) in the cerebral cortex compared to C57/BL6 mice. However, no significant difference in dopamine concentrations was observed by HPLC analysis between Thy1‐&agr;Syn and non‐transgenic C57/BL6 littermates under the control diet. The most striking finding was a favorable effect of DHA on the survival/longevity of Thy1‐&agr;Syn mice (+51% survival rate at 12 months of age). However, dietary DHA supplementation did not have a significant effect on other parameters examined in this study, despite increased striatal dopamine concentrations. While human &agr;Syn monomers and oligomers were detected in the cortex of Thy1‐&agr;Syn mice, the effects of the diets were limited to a small increase of 42 kDa oligomers in insoluble protein fractions upon n‐3 PUFA deprivation. Overall, our data indicate that a diet rich in n‐3 PUFA has a beneficial effect on the longevity of a murine model of &agr;‐synucleinopathy without a major impact on the dopamine system and motor impairments, nor &agr;Syn levels. HighlightsDHA improved the survival of Thy1‐&agr;Syn mice.Thy1‐&agr;Syn mice displayed lower nigral dopaminergic neurons and striatal DAT.NeuN, PSD95, VChAT and synaptophysin cortical levels were reduced in Thy1‐&agr;Syn mice.DHA had no major impact on dopaminergic system and motor impairments.DHA had no major impact on brain &agr;Syn levels.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
α-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation
Bartels, T., Choi, J. G., & Selkoe, D. J. (2011) · Nature · doi:10.1038/nature10324 · Cited by 1,263 · cited 3×
“Most evidence suggests that the equilibrium between monomers and tetramers (58 kDa) is particularly important to the initiation of αSyn misfolding and human synucleinopathies (Barrett and Greenamyre, 2015; Bartels et al., 2011).”
BackgroundNeuropathological assessment of Parkinson’s disease: refining the diagnostic criteria
Dickson, D. W., Braak, H., Duda, J. E., Duyckaerts, C., Gasser, T., Halliday, G. M., Hardy, J., Leverenz, J. B., Del Tredici, K., Wszolek, Z. K., et al. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70238-8 · Cited by 972 · cited 1×
“In sporadic forms of PD, αSyn accumulation and deposition into Lewy bodies is a neuropathological hallmark of the disease, essential for its definitive diagnosis (Dickson et al., 2009).”
BackgroundDyall, S. C. (2015) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2015.00052 · Cited by 943
Schulz-Schaeffer, W. J. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0711-0 · Cited by 627 · cited 2×
“This is further in line with neuropathological observations indicating that an important proportion of αSyn aggregates are localized in axons in human synucleinopathies, leading to the suggestion that αSyn induces synaptic dysfunction before neurodegeneration (Lam et al., 2011; Schulz-Schaeffer, 2010; Wu et al., 2010).”
BackgroundResultn -3 Fatty acids, inflammation and immunity: new mechanisms to explain old actions
Calder, P. C. (2013) · Proceedings of the Nutrition Society · doi:10.1017/s0029665113001031 · Cited by 364 · cited 2×
“…underlying the beneficial properties of DHA include neurotrophic factor secretion (Bousquet et al., 2009), dampening of the inflammatory cascades (Calder, 2013), prevention of oxidative damage (Cardoso et al., 2014), and stimulation of cell survival pathways (Akbar et al., 2005), all processes…”
BackgroundA Progressive Mouse Model of Parkinson’s Disease: The Thy1-aSyn (“Line 61”) Mice
Chesselet, M.-F., Richter, F., Zhu, C., Magen, I., Watson, M. B., & Subramaniam, S. R. (2012) · Neurotherapeutics · doi:10.1007/s13311-012-0104-2 · Cited by 346 · cited 15×
“Among these transgenic germlines, the mouse overexpressing wild-type human αSyn under the neuron-specific Thy1 promoter (Thy1-αSyn) has been extensively characterized (Chesselet et al., 2012; Masliah, 2000) and has been shown to display high levels of αSyn and proteinase K-resistant inclusions containing αSyn in sever…”
BackgroundMethodResultInfluentialda Silva, T. M., Munhoz, R. P., Alvarez, C., Naliwaiko, K., Kiss, Á., Andreatini, R., & Ferraz, A. C. (2008) · Journal of Affective Disorders · doi:10.1016/j.jad.2008.03.008 · Cited by 205 · cited 1×
“Beside possible effects on mood-related symptoms (da Silva et al., 2008), no clinical intervention trial has confirmed a neuroprotective effect of n-3 PUFA in PD.”
BackgroundLam, H. A., Wu, N., Cely, I., Kelly, R. L., Hean, S., Richter, F., Magen, I., Cepeda, C., Ackerson, L. C., Walwyn, W., et al. (2011) · Journal of Neuroscience Research · doi:10.1002/jnr.22611 · Cited by 184
Dietary fat intake, pesticide use, and Parkinson's disease
Kamel, F., Goldman, S. M., Umbach, D. M., Chen, H., Richardson, G., Barber, M. R., Meng, C., Marras, C., Korell, M., Kasten, M., et al. (2014) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2013.09.023 · Cited by 127 · cited 1×
“Furthermore, a meta-analysis has established that intake of n-3 PUFA is associated with a lower PD risk (Kamel et al., 2014).”
BackgroundMori, M. A., Delattre, A. M., Carabelli, B., Pudell, C., Bortolanza, M., Staziaki, P. V., Visentainer, J. V., Montanher, P. F., Del Bel, E. A., & Ferraz, A. C. (2018) · Nutritional Neuroscience · doi:10.1080/1028415x.2017.1290928 · Cited by 89 · cited 3×
“This is in agreement with reported indication of enhanced dopaminergic drive in animals fed with n-3 PUFA (Bousquet et al., 2011a; Chalon, 2006; Coulombe et al., 2016; Delattre et al., 2010; Mori et al., 2017).”
BackgroundResult
Cited by
Microbiome-Gut-Brain Axis and Toll-Like Receptors in Parkinson’s Disease
Caputi, V., & Giron, M. C. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19061689 · Cited by 338
Chidambaram, S. B., Essa, M. M., Rathipriya, A. G., Bishir, M., Ray, B., Mahalakshmi, A. M., Tousif, A. H., Sakharkar, M. K., Kashyap, R. S., Friedland, R. P., et al. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107988 · Cited by 204
Potential Treatment of Parkinson’s Disease with Omega-3 Polyunsaturated Fatty Acids
Li, P., & Song, C. (2022) · Nutritional Neuroscience · doi:10.1080/1028415x.2020.1735143 · Cited by 74
Metadata
- Authors
- Coulombe, K., Kerdiles, O., Tremblay, C., Emond, V., Lebel, M., Boulianne, A.-S., Plourde, M., Cicchetti, F., & Calon, F.
- Venue
- Experimental Neurology
- Publisher
- Elsevier BV
- Published
- 2018-03
- Volume
- 301
- Issue
- Pt A
- Pages
- 39-49
- ISSN
- 0014-4886 (ISSN-L)
- OpenAlex
- W2771914475
- Cited by
- 38
- References
- 11
- FWCI
- 1.95
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Impact of DHA intake in a mouse model of synucleinopathy. https://app.cochat.ai/papers/10.1016/j.expneurol.2017.12.002
- The paper
- Coulombe, K., Kerdiles, O., Tremblay, C., Emond, V., Lebel, M., Boulianne, A.-S., Plourde, M., Cicchetti, F., & Calon, F. (2018). Impact of DHA intake in a mouse model of synucleinopathy. Experimental Neurology. https://doi.org/10.1016/j.expneurol.2017.12.002
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.